References

Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial

10.1016/s0140-6736(21)00213-0 · 2021 · External reference

Semaglutide and cardiovascular outcomes in patients with type 2 diabetes

10.1056/nejmoa1607141 · 2016 · External reference

Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial

10.1093/eurheartj/ehae613 · 2025 · External reference

Semaglutide and cardiovascular outcomes in obesity without diabetes

10.1056/nejmoa2307563 · 2023 · External reference

Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes

10.1056/nejmoa2501006 · 2025 · External reference

Cardiovascular benefits of semaglutide: a systematic review and meta-analysis of randomized controlled trials

10.1186/s12872-025-05278-3 · 2025 · External reference

The adverse effects associated with semaglutide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and Trial Sequential Analysis

10.1186/s12916-025-04486-0 · 2025 · External reference

Effect of semaglutide on insulin sensitivity and cardiometabolic risk factors in adolescents with obesity: the STEP TEENS study

2025 · External reference

Once-weekly semaglutide in adolescents with obesity

10.1056/nejmoa2208601 · 2022 · External reference

8. Obesity and weight management for the prevention and treatment of type 2 diabetes: standards of care in diabetes-2025

2025 · External reference

Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2025

2025 · External reference

Cardiovascular disease and risk management: standards of care in diabetes-2025

2025 · External reference

AGA clinical practice guideline on pharmacological interventions for adults with obesity

10.1053/j.gastro.2022.08.045 · 2022 · External reference

The ethics of ozempic and wegovy

2025 · External reference

Risk of nonarteritic anterior ischemic optic neuropathy in patients prescribed semaglutide

10.1001/jamaophthalmol.2024.2296 · 2024 · External reference

Semaglutide and nonarteritic anterior ischemic optic neuropathy risk among patients with diabetes

10.1001/jamaophthalmol.2025.0349 · 2025 · External reference

Once-weekly semaglutide doubles the five-year risk of nonarteritic anterior ischemic optic neuropathy in a Danish cohort of 424,152 persons with type 2 diabetes

10.1186/s40942-024-00620-x · 2024 · External reference

Use of semaglutide and risk of non-arteritic anterior ischemic optic neuropathy: a Danish-Norwegian cohort study

10.1111/dom.16316 · 2025 · External reference

Semaglutide and nonarteritic anterior ischemic optic neuropathy

10.1001/jamaophthalmol.2024.6555 · 2025 · External reference

Association between semaglutide and nonarteritic anterior ischemic optic neuropathy: a multinational population-based study

10.1016/j.ophtha.2024.10.030 · 2025 · External reference

GLP-1 RAs and risk of nonarteritic anterior ischemic optic neuropathy in older patients with diabetes

10.1001/jamaophthalmol.2025.2299 · 2025 · External reference

GLP-1RA and the risk of non-arteritic anterior ischaemic optic neuropathy in patients with type 2 diabetes: a population-based study

10.1111/dom.70200 · 2026 · External reference

GLP-1 Receptor agonists and sight-threatening ophthalmic complications in patients with type 2 diabetes

10.1001/jamanetworkopen.2025.26321 · 2025 · External reference

Semaglutide or tirzepatide and optic nerve and visual pathway disorders in type 2 diabetes

10.1001/jamanetworkopen.2025.26327 · 2025 · External reference

Real-world evidence assessment of the risk of nonarteritic anterior ischemic optic neuropathy in patients prescribed semaglutide

10.1177/19322968241268050 · 2024 · External reference

Vision impairment following glucagon-like peptide-1 receptor agonist use: is it harmful?

2025 · External reference

The effect of semaglutide and GLP-1 RAs on risk of nonarteritic anterior ischemic optic neuropathy

10.1016/j.ajo.2025.02.025 · 2025 · External reference

GLP-1RA exposure and nonarteritic anterior ischemic optic neuropathy prevalence by diabetes status

10.1001/jamaophthalmol.2025.2332 · 2025 · External reference

Semaglutide: nonarteritic anterior ischemic optic neuropathy in the FDA adverse event reporting system - a disproportionality analysis

10.1016/j.orcp.2025.01.011 · 2025 · External reference

Blinded by the drug? A vigilyze signal linking semaglutide to NAION

10.1007/s10792-025-03760-7 · 2025 · External reference

Multi-database pharmacovigilance assessment of GLP-1 receptor agonist-related ophthalmic risks using advanced signal detection in FAERS and vigibase

10.1007/s40618-025-02712-3 · 2026 · External reference

Association of glucagon-like peptide-1 receptor agonists with optic nerve and retinal adverse events: a population-based observational study across 180 countries

10.1016/j.ajo.2025.05.007 · 2025 · External reference

Association between various dosage forms of semaglutide and ocular adverse events in a real-world setting

10.1186/s12886-025-04096-7 · 2025 · External reference

Non-arteritic anterior ischemic optic neuropathy in an otherwise healthy young adult patient treated with liraglutide and semaglutide for weight loss: a cautionary tale

2025 · External reference

Anterior ischemic optic neuropathy in patients treated with semaglutide: report of four cases with a possible association

10.1186/s12886-025-03958-4 · 2025 · External reference

Bilateral non-arteritic anterior ischemic optic neuropathy following weight loss from semaglutide (Ozempic): a case report

10.1080/01658107.2024.2411260 · 2025 · External reference

Ophthalmic complications associated with the antidiabetic drugs semaglutide and tirzepatide

10.1001/jamaophthalmol.2024.6058 · 2025 · External reference

Retrospective clinical analysis of non-arteritic anterior ischemic optic neuropathy (NAION) in patients using semaglutide

2025 · External reference

Is semaglutide linked to NAION? A case report on a rare ocular complication

10.3390/reports8030149 · 2025 · External reference

Non arteritic ischemic optic neuropathy in a patient taking semaglutide: is there a relation? A case report and a review of the literature

10.1177/11206721251331655 · 2025 · External reference

Reexamining the incidence of nonarteritic anterior ischemic optic neuropathy: a rochester epidemiology project study

10.1097/wno.0000000000002102 · 2024 · External reference

Current concepts in the diagnosis, pathogenesis and management of nonarteritic anterior ischaemic optic neuropathy

10.1038/eye.2014.144 · 2015 · External reference

Semaglutide and non-arteritic anterior ischemic optic neuropathy: a systematic review

2025 · External reference

Semaglutide and non-arteritic anterior ischaemic optic neuropathy: review and interpretation of reported association

10.1111/aos.17473 · 2025 · External reference

What the diabetologist needs to know about the risk of non-arteritic anterior ischaemic optic neuropathy and GLP-1 receptor agonist use in patients with type 2 diabetes

10.1016/j.diabet.2025.101664 · 2025 · External reference

In the eye of controversy: a deeper look into the impact of glucagon-like peptide-1 receptor agonists on diabetic retinopathy and nonarteritic anterior ischemic optic neuropathy

10.1016/j.jcjd.2025.07.002 · 2025 · External reference

Ocular effects of GLP-1 receptor agonists: a review of current evidence and safety concerns

10.3390/diabetology6100117 · 2025 · External reference

Semaglutide and the retina: weighing evidence against concern

10.1016/j.jdiacomp.2025.109148 · 2025 · External reference

Semaglutide in modern medicine: therapeutic opportunities in obesity and the emerging challenge of NAION – a narrative review

10.5114/fmpcr.2025.150180 · 2025 · External reference

GLP-1 receptor agonists and non-arteritic anterior ischemic optic neuropathy: what an endocrinologist needs to know

2025 · External reference

Nonarteritic anterior ischemic optic neuropathy and semaglutide: what is this all about?

10.59556/japi.72.0621 · 2024 · External reference

Ocular adverse events with semaglutide: a systematic review and meta-analysis

10.1001/jamaophthalmol.2025.2489 · 2025 · External reference

Glucagon-like peptide 1 (GLP1) receptor agonists and risk for ischemic optic neuropathy: a meta-analysis of randomised controlled trials

10.1111/dom.16076 · 2025 · External reference

Are synthetic incretins associated with ischaemic optic neuropathy?

10.1038/s41433-025-03718-0 · 2025 · External reference

Addressing the risk of ocular complications of GLP-1RAs; a multi-disciplinary expert consensus

10.1111/dom.70160 · 2025 · External reference

Unresolved reference

External reference

Unresolved reference

External reference

Unresolved reference

External reference

Unresolved reference

External reference

Unresolved reference

External reference

Unresolved reference

External reference

The PRISMA 2020 statement: an updated guideline for reporting systematic reviews

10.1186/s13643-021-01626-4 · 2021 · External reference

Language bias in randomised controlled trials published in English and German

10.1016/s0140-6736(97)02419-7 · 1997 · External reference

Direction and impact of language bias in meta-analyses of controlled trials: empirical study

10.1093/ije/31.1.115 · 2002 · External reference

Ignoring non-English-language studies may bias ecological meta-analyses

10.1002/ece3.6368 · 2020 · External reference

Unresolved reference

External reference

Unresolved reference

External reference

A re-evaluation of fixed effect(s) meta-analysis

10.1111/rssa.12275 · 2018 · External reference

Quantifying heterogeneity in a meta-analysis

10.1002/sim.1186 · 2002 · External reference

Basics of meta-analysis: I2 is not an absolute measure of heterogeneity

10.1002/jrsm.1230 · 2017 · External reference

Empirical comparison of publication bias tests in meta-analysis

10.1007/s11606-018-4425-7 · 2018 · External reference

Unresolved reference

External reference

Umbrella reviews.

10.46658/jbimes-24-08 · 2024 · External reference

AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both

2017 · External reference

Does semaglutide increase the risk of non-arteritic anterior ischemic optic neuropathy? A systematic review and meta-analysis of emerging evidence

10.1016/j.apjo.2025.100245 · 2026 · External reference

Glucagon-like peptide-1 receptor agonists and the risk of nonarteritic anterior ischaemic optic neuropathy: a systematic review and meta-analysis of observational studies

10.1111/dom.70013 · 2025 · External reference

Nonarteritic anterior ischemic optic neuropathy and glucagon-like peptide-1 receptor agonists: evaluating a potential association

10.1016/j.ejim.2025.05.011 · 2025 · External reference

1972-LB: glucagon-like peptide 1 receptor agonists and NAION—a systematic review and meta-analysis

2025 · External reference

Disproportionality analysis on semaglutide and nonarteritic anterior ischemic optic neuropathy in the FDA adverse event reporting system: an emerging pharmacovigilance signal?

10.1016/j.orcp.2025.03.001 · 2025 · External reference

Association between socioeconomic factors and semaglutide use for weight loss: a population-based cross-sectional study in Denmark

10.1016/j.lanepe.2025.101398 · 2025 · External reference

Incidence and causes of overdiagnosis of optic neuritis

10.1001/jamaophthalmol.2017.5470 · 2018 · External reference

Population-level impact of semaglutide 2.4 mg in patients with obesity or overweight and cardiovascular disease: a modelling study based on the SELECT trial

10.1111/dom.16370 · 2025 · External reference

The composite number needed to treat for semaglutide in populations with overweight or obesity and established cardiovascular disease without diabetes

10.1007/s12325-025-03176-w · 2025 · External reference

Retinopathy, neuropathy, and foot care: standards of care in diabetes-2025

2025 · External reference

Ocular safety of glucagon-like peptide-1 receptor agonists: insights and unanswered questions. Authors’ reply

10.20452/pamw.17046 · 2025 · External reference

Ocular safety of glucagon-like peptide-1 receptor agonists: insights and unanswered questions

10.20452/pamw.17045 · 2025 · External reference

Prevalence and incidence of non-arteritic anterior ischaemic optic neuropathy in South Korea: a nationwide population-based study

10.1136/bjophthalmol-2017-311140 · 2018 · External reference

Reversable bilateral ischemic optic neuropathy following semaglutide discontinuation with crowded optic discs.

2025 · External reference